Abstract
We undertook a study to compare the safety of intravenous (i.v.) versus oral hydration to prevent nephrotoxicity associated with the use of foscarnet for induction therapy of cytomegalovirus (CMV) infection in HIV-infected persons. Patients, given foscarnet at a dose of 90mg/kg every 12h, were randomized to receive either i.v. or oral hydration. Thirty-seven patients were given i.v. hydration and 44 were given oral hydration. Median duration of therapy for both groups was 17 days. There was no difference between the 2 groups in either serious adverse events or rise of creatinine to ≥2.0mg/dl. However, serum creatinine, while generally remained within normal limits, increased more in patients who received oral hydration after 10 days of therapy (significant only by slope analysis, P < 0.05). Although i.v. hydration provided better protection against nephrotoxicity, oral hydration was relatively safe and convenient provided that creatinine clearance (CrCl) is monitored closely.
Original language | English (US) |
---|---|
Pages (from-to) | 640-647 |
Number of pages | 8 |
Journal | International Journal of STD and AIDS |
Volume | 11 |
Issue number | 10 |
DOIs | |
State | Published - 2000 |
Keywords
- Cytomegalovirus infection
- Foscarnet
- Intravenous hydration HIV
- Nephrotoxicity
- Oral hydration
ASJC Scopus subject areas
- Dermatology
- Public Health, Environmental and Occupational Health
- Microbiology (medical)
- Immunology